The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 2 of the 12 sources its claims cite were checked for support.
Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.
Open accessAbstract
To define glycemic thresholds for activation of glucose counterregulatory systems and for symptoms of hypoglycemia, we measured these during stepped reductions in the plasma glucose concentration (in six 10-mg/dl hourly steps) from 90 to 40 mg/dl under hyperinsulinemic clamp conditions, and compared these with the same measurements during euglycemia (90 mg/dl) under the same conditions over 6 h in 10 normal humans. Arterialized venous plasma glucose concentrations were used to calculate glycemic thresholds of 69 +/- 2 mg/dl for epinephrine secretion, 68 +/- 2 mg/dl for glucagon secretion, 66 +/- 2 mg/dl for growth hormone secretion, and 58 +/- 3 mg/dl for cortisol secretion. In contrast, the glycemic threshold for symptoms was 53 +/- 2 mg/dl, significantly lower than the thresholds for epinephrine (P less than 0.001), glucagon (P less than 0.001), and growth hormone (P less than 0.01) secretion. Thus, the glycemic thresholds for activation of glucose counterregulatory systems during decrements in plasma glucose lie within or just below the physiologic plasma glucose concentration range, and are substantially higher than the threshold for hypoglycemic symptoms in normal humans. These findings provide further support for the concept that glucose counterregulatory systems are involved in the prevention, as well as the correction, of hypoglycemia.
Overview
CoChat Summary
TL;DR
In normal humans, stepped hyperinsulinemic hypoglycemia showed that glucose counterregulatory hormone responses begin at higher plasma glucose levels than hypoglycemic symptoms. The authors conclude that counterregulatory systems are activated within or just below the physiologic glucose range, supporting their role in preventing as well as correcting hypoglycemia.
Key findings
- Calculated arterialized venous glycemic thresholds were 69±2 mg/dl for epinephrine, 68±2 mg/dl for glucagon, 66±2 mg/dl for growth hormone, 58±3 mg/dl for cortisol, and 51±3 mg/dl for norepinephrine.
- The symptom threshold was 53±2 mg/dl, significantly lower than thresholds for epinephrine (P < 0.001), glucagon (P < 0.001), and growth hormone (P < 0.01).
- The cortisol threshold tended to exceed the symptom threshold but not significantly; the norepinephrine threshold was similar to the symptom threshold.
- Mean symptom score began to increase during the 70–60 mg/dl step and clearly exceeded control values during the 60–50 mg/dl step.
Methods
- Ten normal young adults (nine men, one woman; age 23–34 yr, mean±SD 26±3 yr) underwent two 6-h studies after an overnight fast: an experimental stepped-glucose study and a euglycemic control study.
- Under hyperinsulinemic clamp conditions, plasma glucose was lowered in six 10-mg/dl hourly steps from 90 to 40 mg/dl in the experimental study, while the control study clamped glucose at 90 mg/dl; arterialized venous samples were drawn every 10 min, and symptoms were self-scored 0–10 for 12 symptoms.
- Glycemic thresholds were calculated as the mean glucose concentration at which each parameter first exceeded the 95% confidence interval from euglycemic control data, after adjusting baseline data to zero; thresholds were compared with a t test.
Limitations
- The authors state that thresholds were determined in a small, reasonably homogeneous group of normal young adults and should not be extrapolated uncritically to other conditions.
- They note the thresholds are conservative estimates that may be lower than biologic thresholds because responses must have begun before values exceeded the 95% confidence intervals; inspection suggested epinephrine and growth hormone thresholds may be >70 mg/dl, perhaps >80 mg/dl.
- They also state that arterialized venous values may not be comparable to venous glucose under other conditions, that cortisol’s lower threshold might reflect unmeasured ACTH response delay, and that steady state was not achieved in the control study; the design could not distinguish reduced plasma glucose per se from insulin resistance induced by counterregulatory activation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 4 Not checked · 32 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Arterialized venous plasma glucose concentrations were used to calculate glycemic thresholds of 69±2 mg/dl for epinephrine secretion, 68±2 mg/dl for glucagon secretion, 66±2 mg/dl for growth hormone secretion, and 58±3 mg/dl for cortisol secretion.”
- Also stated in: § Discussion · p. 3 · plain
“the calculated glycemic thresholds for epinephrine (69±2 mg/dl), glucagon (68±2), and growth hormone (66±2 mg/dl) secretion lie just below the physiologic range.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 3 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, the glycemic threshold for symptoms was 53±2 mg/dl, significantly lower than the thresholds for epinephrine (P < 0.001), glucagon (P < 0.001), and growth hormone (P < 0.01) secretion.”
- Also stated in: § Discussion · p. 3 · plain
“the glycemic thresholds for activation of glucose counterregulatory systems are substantially higher than the threshold for hypoglycemic symptoms (53±2 mg/dl).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 3 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The glycemic threshold for an increment in plasma norepinephrine (51±3 mg/dl) was similar to that for symptoms.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Arterialized venous plasma glucose concentrations were used to calculate glycemic thresholds of 69±2 mg/dl for epinephrine secretion, 68±2 mg/dl for glucagon secretion, 66±2 mg/dl for growth hormone secretion, and 58±3 mg/dl for cortisol secretion.”
- Also stated in: § Discussion · p. 3 · plain
“the calculated glycemic thresholds for epinephrine (69±2 mg/dl), glucagon (68±2), and growth hormone (66±2 mg/dl) secretion lie just below the physiologic range.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 3 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The glycemic threshold for increments in plasma cortisol (58±3 mg/dl) was lower than those for increments in epinephrine, glucagon, or growth hormone.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
17 more claims
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“On the other hand, the glycaemic thresholds of cortisol found in the present study (3.61 _+ 0.06 mmol/1) are lower, i.e. a smaller decrease in plasma glucose is sufficient to elicit a response, as compared to previous studies [1,3] using a similar methodological approach.”
From Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans (1994) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and the glycaemic threshold for activation of glucose counter-regulatory systems (approximately 3.6-3.9mmol/l [65-70 mg/dl] [6][7][8][9])”
From Preventing hypoglycaemia: what is the appropriate glucose alert value? (2009) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“It is higher than the glucose levels required to produce symptoms in non-diabetic individuals (approximately 2.8-3.1 mmol/l [50-55 mg/dl] [6-9])”
From Preventing hypoglycaemia: what is the appropriate glucose alert value? (2009) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Regarding the glycaemic thresholds of glucagon, growth hormone and adrenaline, the results of the present studies confirm previous reports [1,3].”
The cited source says what the claim attributes to it.
In the citing paper
“two studies using a graded stepped hypoglycaemic clamp reported similar results [18, 19].”
From Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review (2022) · cites this paper as [19]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 2
“89±2 (90), 80±1 (80), 70±1 (70), 62±1 (60), 48±1 (50), and 43±2 (40) mg/dl.”
§ Results · p. 2
“| 180-240 | 90±2 | 9.2±0.8 | 62±2 | 5.6±0.9* |”
Citations
Cites
Immunoassay of insulin with insulin-antibody precipitate
HALES, C., & RANDLE, P. (1963) · Biochemical Journal · doi:10.1042/bj0880137 · Cited by 2,638
Effect of Ischemia on Known Substrates and Cofactors of the Glycolytic Pathway in Brain
Lowry, O. H., Passonneau, J. V., Hasselberger, F. X., & Schulz, D. W. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51740-3 · Cited by 2,221
Hormone-fuel interrelationships during fasting.
Cahill, G. F., Herrera, M. G., Morgan, A. P., Soeldner, J. S., Steinke, J., Levy, P. L., Reichard, G. A., & Kipnis, D. M. (1966) · Journal of Clinical Investigation · doi:10.1172/jci105481 · Cited by 1,036
Dose-response characteristics for effects of insulin on production and utilization of glucose in man
Rizza, R. A., Mandarino, L. J., & Gerich, J. E. (1981) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1981.240.6.e630 · Cited by 703
Colorimetric ultramicro method for the determination of free fatty acids
Novák, M. (1965) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39315-9 · Cited by 639
A Sensitive Double Antibody Immunoassay for Human Growth Hormone in Plasma
SCHALCH, D. S., & PARKER, M. L. (1964) · Nature · doi:10.1038/2031141a0 · Cited by 635
Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics
Kuzuya, H., Blix, P. M., Horwitz, D. L., Steiner, D. F., & Rubenstein, A. H. (1977) · Diabetes · doi:10.2337/diab.26.1.22 · Cited by 603
Role of Glucagon, Catecholamines, and Growth Hormone in Human Glucose Counterregulation
Rizza, R. A., Cryer, P. E., & Gerich, J. E. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109464 · Cited by 421
Self-citationWhite, N. H., Skor, D. A., Cryer, P. E., Levandoski, L. A., Bier, D. M., & Santiago, J. V. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303033080903 · Cited by 391
Self-citationPlasma noradrenaline correlates to sympathetic muscle nerve activity in normotensive man
WALLIN, B. G., SUNDLÖF, G., ERIKSSON, B., DOMINIAK, P., GROBECKER, H., & LINDBLAD, L. E. (1981) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1981.tb06706.x · Cited by 316
Cited by
Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1553 · Cited by 2,044
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558
Self-citation
Metadata
- Authors
- Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E.
- Affiliations
- Washington University in St. Louis (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1987-03-01
- Volume
- 79
- Issue
- 3
- Pages
- 777-781
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC424197
- OpenAlex
- W2087707740
- Semantic Scholar
- 04e9668073ba5c3c773cd60e2a3f9b07a954bf4b
- Cited by
- 394
- References
- 38
- Citations by year
- 2026: 10 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 14 · 2021: 11 · 2020: 6 · 2019: 6 · 2018: 13 · 2017: 13 · 2016: 10 · 2015: 12 · 2014: 12 · 2013: 13 · 2012: 12
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60am020579-08, 2r01am027085-06)
- National Center for Research Resources (RR.00036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- hypoglycemia, glycemic thresholds, glucose counterregulation, hypoglycemic symptoms, epinephrine secretion, glucagon secretion, growth hormone secretion, cortisol secretion, hyperinsulinemic-euglycemic clamp, plasma glucose, hypoglycemia prevention
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Epinephrine, Fatty Acids, Nonesterified, Female, Glucagon, Humans, Hydrocortisone, Hydroxybutyrates, Hypoglycemia, Insulin, Lactates, Male, Norepinephrine, Growth Hormone, Lactic Acid, 3-Hydroxybutyric Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. https://app.cochat.ai/papers/10.1172/jci112884
- The paper
- Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E. (1987). Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. Journal of Clinical Investigation. https://doi.org/10.1172/jci112884
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.